Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.

Tytuł:: Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
Autorzy:: Nakanishi S; Department of Urology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan. .
Goya M; Department of Urology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Tamaki M; Naha City Hospital, Naha, Okinawa, Japan.
Oshiro T; Naha City Hospital, Naha, Okinawa, Japan.
Saito S; Department of Urology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Źródło:: BMC research notes [BMC Res Notes] 2021 Jun 03; Vol. 14 (1), pp. 227. Date of Electronic Publication: 2021 Jun 03.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: London : Biomed Central, 2008.
MeSH Terms:: Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Androgen Antagonists/therapeutic use ; Hormones ; Humans ; Male ; Neoplasm Grading ; Prostate-Specific Antigen ; Retrospective Studies
References:: Crit Rev Oncol Hematol. 2013 Jan;85(1):82-93. (PMID: 22705096)
J Urol. 2010 Jul;184(1):162-7. (PMID: 20483155)
Prostate Cancer Prostatic Dis. 2014 Mar;17(1):34-9. (PMID: 24080993)
Oncogene. 2013 Dec 5;32(49):5501-11. (PMID: 23752182)
Nat Clin Pract Urol. 2009 Feb;6(2):76-85. (PMID: 19198621)
Cancer Med. 2016 Mar;5(3):407-14. (PMID: 26765317)
Clin Cancer Res. 2010 Jan 1;16(1):203-11. (PMID: 20008841)
Lancet. 2016 Mar 19;387(10024):1163-77. (PMID: 26719232)
N Engl J Med. 2017 Jul 27;377(4):352-360. (PMID: 28578607)
Cancer Res Treat. 2010 Mar;42(1):12-7. (PMID: 20369046)
BMC Urol. 2018 May 8;18(1):32. (PMID: 29739368)
Medicine (Baltimore). 2017 Sep;96(36):e7823. (PMID: 28885333)
BMC Cancer. 2015 May 01;15:338. (PMID: 25929438)
World J Urol. 2015 Sep;33(9):1263-8. (PMID: 25354720)
N Engl J Med. 2017 Jul 27;377(4):338-351. (PMID: 28578639)
Prostate. 2011 Aug 1;71(11):1189-97. (PMID: 21656829)
N Engl J Med. 2015 Aug 20;373(8):737-46. (PMID: 26244877)
J Clin Oncol. 2008 Mar 1;26(7):1148-59. (PMID: 18309951)
World J Clin Cases. 2020 Jan 6;8(1):54-67. (PMID: 31970170)
J Urol. 2003 Jan;169(1):164-9. (PMID: 12478127)
Eur Urol. 2014 Jan;65(1):3-6. (PMID: 24120464)
Cancer. 1988 Jan 1;61(1):195-202. (PMID: 3334948)
Cancer Sci. 2015 May;106(5):497-504. (PMID: 25728850)
Cancer. 2009 Mar 1;115(5):981-7. (PMID: 19152438)
J Urol. 2002 Oct;168(4 Pt 1):1423-6. (PMID: 12352409)
Clin Genitourin Cancer. 2011 Sep;9(1):31-8. (PMID: 21705286)
J Urol. 2009 Jun;181(6):2520-4; discussion 2525. (PMID: 19371894)
Lancet Oncol. 2013 Feb;14(2):149-58. (PMID: 23306100)
J Clin Oncol. 2006 May 1;24(13):1982-9. (PMID: 16648498)
Contributed Indexing:: Keywords: 3-Month %PSA; Prostate cancer; Time to CRPC; mHSPC
Substance Nomenclature:: 0 (Androgen Antagonists)
0 (Hormones)
EC 3.4.21.77 (Prostate-Specific Antigen)
Entry Date(s):: Date Created: 20210604 Date Completed: 20210607 Latest Revision: 20210607
Update Code:: 20240104
PubMed Central ID:: PMC8176613
DOI:: 10.1186/s13104-021-05641-5
PMID:: 34082809
: Czasopismo naukowe

Pełny tekst

Objective: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.
Results: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥ 8 (p = 0.004), an extent of disease value (EOD) of ≥ 2 (p = 0.004), and a 3-month PSA level > 1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. A 3-month PSA level > 1% of the pretreatment level was an independent predictor of OS (p = 0.004). Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level > 1% of the pretreatment level correlated with a poor prognosis.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja